Oral semaglutide (Rybelsusยฎ) receives FDA approval for the treatment of type 2 diabetes

The FDA has issued a press release regarding the approval of the first oral GLP-1 treatment for type 2 diabetes. Novo Nordisk also issued a press release on Rybelsusยฎ. Novo Nordisk in the US issued a separate press release. In terms of future peak sales this might be the most important FDA approval of any …